>>Signaling Pathways>> Immunology/Inflammation>> NOD-like Receptor (NLR)>>NOD-IN-1

NOD-IN-1

Catalog No.GC31657

NOD-IN-1은 각각 5.74μM 및 6.45μM의 IC50을 갖는 뉴클레오티드 결합 올리고머화 도메인(NOD) 유사 수용체인 NOD1 및 NOD2의 강력한 혼합 억제제입니다.

Products are for research use only. Not for human use. We do not sell to patients.

NOD-IN-1 Chemical Structure

Cas No.: 132819-92-2

Size 가격 재고 수량
10mM (in 1mL DMSO)
US$102.00
재고 있음
1mg
US$72.00
재고 있음
5mg
US$135.00
재고 있음
10mg
US$209.00
재고 있음
50mg
US$702.00
재고 있음
100mg
US$990.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

NOD-IN-1 is a potent mixed inhibitor of nucleotide-binding oligomerization domain (NOD)-like receptors, NOD1 and NOD2, with IC50 of 5.74 μM and 6.45 μM, respectively.

NOD-IN-1 (compound 4) is potent mixed inhibitor of NOD1 and NOD2, displaying a balanced inhibitory activity on both targets in the low micromolar range. NOD-IN-1 (IC50 (NOD1)=5.74 μM; IC50 (NOD2)=6.45 μM) is identified as the best of the series, possessing NOD1- and NOD2-inhibitory activities in the lower micromolar range. These results show that NOD-IN-1 is 7-fold less potent than Noditinib-1 in terms of NOD1 inhibition and completely devoid of selective activity for NOD1 or NOD2 as opposed to Noditinib-1. NOD-IN-1 exhibits balanced dual activities of less than 10 μM on the two targets[1].

[1]. Kecek Plesec K, et al. Identification of indole scaffold-based dual inhibitors of NOD1 and NOD2. Bioorg Med Chem. 2016 Nov 1;24(21):5221-5234.

리뷰

Review for NOD-IN-1

Average Rating: 5 ★★★★★ (Based on Reviews and 35 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for NOD-IN-1

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.